Abbott's device sales drive profit beat, but shares fall as forecast disappoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
April 18, 2024 6:19 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $128.00) while maintaining a Outperform rating.
The analyst comments "ABT delivered a Q1 Rev/EPS upside of $80MM/$0.03, respectively, and tightened its FY24 guidance range. Despite a strong Q1... More
Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
April 17, 2024 7:42 AM EDTAbbott Laboratories (NYSE: ABT) reported better-than-expected first-quarter top and bottom lines and narrowed its earnings guidance for the full fiscal 2024.
Shares fell over 2% in premarket trading Wednesday.
The healthcare company posted earnings per share (EPS) of $0.98, beating the consensus estimate of $0.96. Revenue... More
